Robert S. Radie Sells 15,000 Shares of Egalet Corp. (EGLT) Stock
Egalet Corp. (NASDAQ:EGLT) insider Robert S. Radie sold 15,000 shares of the firm’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $7.47, for a total transaction of $112,050.00. Following the sale, the insider now owns 234,900 shares in the company, valued at $1,754,703. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Egalet Corp. (NASDAQ:EGLT) opened at 6.91 on Friday. The firm has a 50-day moving average of $7.49 and a 200-day moving average of $6.59. The company’s market capitalization is $169.59 million. Egalet Corp. has a one year low of $4.34 and a one year high of $11.96.
Egalet Corp. (NASDAQ:EGLT) last released its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. Egalet Corp. had a negative return on equity of 86.03% and a negative net margin of 244.57%. The firm had revenue of $3.45 million for the quarter, compared to analyst estimates of $3.83 million. During the same quarter in the previous year, the business posted ($1.03) earnings per share. Egalet Corp.’s revenue for the quarter was up 259.4% on a year-over-year basis. Analysts forecast that Egalet Corp. will post ($3.48) earnings per share for the current year.
Several large investors have recently made changes to their positions in EGLT. ProShare Advisors LLC boosted its stake in shares of Egalet Corp. by 16.2% in the second quarter. ProShare Advisors LLC now owns 21,386 shares of the specialty pharmaceutical company’s stock worth $106,000 after buying an additional 2,977 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Egalet Corp. during the second quarter worth $125,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Egalet Corp. during the second quarter worth $177,000. Teachers Advisors Inc. bought a new stake in shares of Egalet Corp. during the second quarter worth $180,000. Finally, California State Teachers Retirement System bought a new stake in shares of Egalet Corp. during the second quarter worth $230,000. Institutional investors and hedge funds own 67.18% of the company’s stock.
Several analysts have recently commented on EGLT shares. Cantor Fitzgerald restated a “buy” rating on shares of Egalet Corp. in a research report on Tuesday, June 28th. Zacks Investment Research downgraded shares of Egalet Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Finally, Gabelli began coverage on shares of Egalet Corp. in a report on Tuesday, September 13th. They issued a “buy” rating and a $9.50 price target on the stock.
About Egalet Corp.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corp. and related companies with MarketBeat.com's FREE daily email newsletter.